Carlyle completed the acquisition of a majority stake in Saama for $430m.

Carlyle completed the acquisition of a majority stake in Saama, an AI clinical analytics platform company, for $430m. A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle. “The life sciences industry is experiencing a massive shift in strategic approaches to accelerating drug development as a result of the Covid-19 pandemic, and AI-driven analytics solutions like Saama’s LSAC are at the forefront. These solutions’ role in successfully enabling the delivery of Covid-19 vaccines and therapies to patients in mere months was the litmus test for the future of drug development. This investment by Carlyle and leading healthcare-focused venture funds reflects the value they see in Saama’s leadership of this new era and the promise offered by our state-of-the-art solutions," Suresh Katta, Saama Founder and CEO.